"Межрегиональный клинико-диагностический центр (МКДЦ) – это территория здоровья, где слияние архитектуры и медицины оказывает положительное влияние на физическое и эмоциональное благополучие пациентов. В структуре МКДЦ функционирует многопрофильный Центр медицинских и оздоровительных программ, предоставляющий индивидуальные медицинские решения. Современное техническое оснащение, безупречный сервис, высокопрофессиональные врачи и вежливый персонал ждут вас в нашем центре."

During the past decade, Interregional Clinical Diagnostic Center conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 12 clinical trials were completed, i.e. on average, 63.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 11 clinical trials were completed. i.e. 157.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Interregional Clinical Diagnostic Center" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Actelion" with 2 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Camurus AB" with 2 trials sponsored and "Ionis Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 9 trials in total.

According to Clinical.Site data, the most researched conditions in "Interregional Clinical Diagnostic Center" are "Acromegaly" (5 trials), "Alzheimer's Disease" (5 trials), "Alzheimer Disease" (2 trials), "Severe Hypertriglyceridemia" (2 trials) and "Chronic Thromboembolic Pulmonary Hypertension" (1 trials). Many other conditions were trialed in "Interregional Clinical Diagnostic Center" in a lesser frequency.

Most popular intervention types in "Interregional Clinical Diagnostic Center" are "Drug" (20 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Gantenerumab" (4 trials), "Crenezumab" (3 trials), "CAM2029 (octreotide subcutaneous depot)" (2 trials) and "Fenofibrate" (2 trials). Other intervention names were less common.

The vast majority of trials in "Interregional Clinical Diagnostic Center" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Interregional Clinical Diagnostic Center". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Interregional Clinical Diagnostic Center, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Interregional Clinical Diagnostic Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".